{
    "symbol": "SPRO",
    "quarter": 1,
    "year": 2022,
    "date": "2022-05-16 21:42:05",
    "content": "  Before we begin, I'd like to remind you that some of the information contained in the news release and on this conference call contains forward-looking statements based on our current expectations; including statements about the potential review status and prospects of approval for tebipenem HBr; potential value of tebipenem HBr if approved and the prospects of partnership and/or other opportunities for the tebipenem HBr program; the plans for the company's ongoing development of SPR720 and SPR206; the design, initiation, timing, progress and results of the company's preclinical studies; and the clinical trials and its research and development programs; management's assessment of the results of such preclinical studies and clinical trials; the company's cash forecast and anticipated expenses and the sufficiency of its cash resources."
}